Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic Syndromes 6Leukemia, Myeloid, Acute 5Leukemia 5Lymphoma, Non-Hodgkin 4Primary Immunodeficiency Diseases 3Hematologic Neoplasms 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Lymphoma 2Hemoglobinopathies 2Fanconi Anemia 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Thymoma 1Thymic epithelial tumor 1Stomach Neoplasms 1Recurrence 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Graft vs Host Disease 1

Interventions

Tacrolimus 8Methotrexate 7Cyclophosphamide 7Mycophenolic Acid 6Sirolimus 5Busulfan 5fludarabine phosphate 4fludarabine 4Peripheral Blood Stem Cell Transplantation 4Melphalan 3Cyclosporine 3thymoglobulin 2ibrutinib 2Whole-Body Irradiation 2Vorinostat 2Filgrastim 2Antilymphocyte Serum 2plerixafor 1carfilzomib 1aldesleukin 1Transplantation Conditioning 1Thiotepa 1Pentostatin 1Mesna 1Leukocyte Count 1KRN 7000 1Hematopoietic Stem Cell Transplantation 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Graft vs Host Disease × AP 1903 reagent × Clear all
NCT01744223 2022-07-12

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Bellicum Pharmaceuticals

Phase 1/2 Active not recruiting
36 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡